Major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) are highly prevalent and debilitating conditions. Despite the widespread use of medication and psychotherapy, a significant portion of patients experience inadequate responses.
Transcranial magnetic stimulation (TMS) offers a non-invasive, safe and effective approach for these treatment-resistant cases. This article explores the evidence supporting the use of TMS in Atlanta’s mental health landscape.
Mental Health Nationwide and in Georgia
According to the National Institute of Mental Health (NIMH), major depressive disorder affects a substantial portion of the population, with 20.1% of adolescents (ages 12-17) and 8.3% of adults experiencing a major depressive episode annually.1 Obsessive-compulsive disorder affects an estimated 1.2% of U.S. adults each year.2
Examining Georgia’s statistics provides a more localized perspective. According to the Substance Abuse and Mental Health Services Administration’s (SAMHSA) 2021 National Survey on Drug Use and Health (NSDUH) State Estimates of Substance Use and Mental Disorders, 8.47% of Georgia residents aged 18 or older reported experiencing a major depressive episode in the past year.3 Additionally, 4.7% had serious thoughts of suicide and 1.45% made suicide plans.3
The Kaiser Family Foundation’s analysis of the U.S. Census Household Pulse Survey (2020-2022) further highlights that 29.4% of adults in Georgia reported symptoms of anxiety and/or depression, with 28.3% unable to access counseling or therapy.4
From Discovery to Modern Clinical Applications
The concept of leveraging magnetic fields for brain stimulation dates back to the early 19th century. The development of modern TMS is credited to British physician Dr. Anthony Barker in the 1980s.
Barker’s initial investigations focused on the motor cortex, demonstrating its ability to elicit muscular twitches, which paved the way for exploring TMS in psychiatry. In the 1990s, clinical trials began investigating TMS for depression, with Pascual-Leone et al. (1996) providing the first evidence of repetitive TMS (rTMS) efficacy in treatment-resistant depression (TRD).5
TMS works by delivering magnetic pulses to specific brain areas, commonly the left dorsolateral prefrontal cortex (DLPFC), associated with mood regulation. These pulses induce electrical currents that modulate neuronal activity, enhancing or inhibiting neural circuits involved in depression and other psychiatric disorders.
Although the exact mechanisms remain an area of active research, TMS is believed to influence neuroplasticity and neurotransmitter release, contributing to its therapeutic effects.
The Rise of rTMS: A Non-invasive Approach for Treatment-Resistant Cases
Unlike electroconvulsive therapy (ECT), TMS offers a non-invasive alternative. During an rTMS session, a magnetic coil positioned near the scalp delivers brief magnetic pulses, stimulating targeted brain regions. These pulses modulate neuronal activity, potentially influencing mood regulation and alleviating symptoms.
rTMS is well-established for treating TRD, defined as depression unresponsive to at least two different medication trials. The STAR*D trial highlighted that less than one in three patients with depression achieve remission with a single antidepressant trial.6 Large-scale studies and meta-analyses report response rates of 40% to 60% and remission rates exceeding 30% using TMS in the acute treatment of major depression.7, 8 Intermittent theta-burst stimulation (iTBS), a significantly faster treatment option, is also approved by the U.S. Food and Drug Administration for TRD.9 Stanford Neuromodulation Therapy (SNT), a five-day, multi-treatment iTBS approach, is another emerging option, though further trials are needed to determine its durability and comparative effectiveness.10
Expanding Horizons: Potential Applications Beyond Depression and OCD
Approximately 40%-60% of OCD patients do not improve with medication or behavioral therapies.11 In 2018, the FDA approved TMS for OCD, supported by studies like Carmi et al. (2019), which demonstrated significant symptom reduction with rTMS targeting the supplementary motor area (SMA).12
Safety and Tolerability Profile: A Key Advantage
A significant advantage of rTMS is its safety profile. Unlike medications, rTMS exhibits minimal systemic side effects. The most common side effects are mild and transient, such as scalp discomfort and headache, typically resolving on their own or with simple pain management strategies.13 This favorable risk profile makes rTMS particularly attractive for patients who experience medication side effects or have medical conditions limiting their medication options.
The Future of TMS: Refining Techniques and Broadening Applications
The field of TMS is rapidly evolving. Researchers are investigating novel protocols, targeting distinct brain regions and exploring TMS in combination with other therapies to optimize outcomes. New coil designs and navigation techniques promise enhanced targeting accuracy and potentially expanded treatable conditions. Magnetic peripheral nerve stimulation (mPNS), a relatively new FDA-approved technique for chronic pain relief, represents another exciting development.14
In Atlanta, the increasing availability of TMS therapy in hospitals and private practices enhances accessibility for patients seeking innovative treatments. As research continues and treatment protocols are refined, TMS is poised to become an integral component of psychiatric care.
TMS offers a non-invasive, safe and effective approach for treating a range of debilitating psychiatric conditions, particularly treatment-resistant depression and OCD. With ongoing research and development, TMS has the potential to revolutionize the management of mental health disorders in Atlanta and beyond.
References
1. National Institute of Mental Health. Major Depressive Disorder. https://www.nimh.nih.gov/health/topics/depression
2. National Institute of Mental Health. Obsessive-Compulsive Disorder. https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd
3. Substance Abuse and Mental Health Services Administration. 2021 National Survey on Drug Use and Health (NSDUH) State Estimates of Substance Use and Mental Disorders. https://www.samhsa.gov/data/report/2021-2022-nsduh-state-estimates-substance-use-and-mental-disorders
4. Kaiser Family Foundation. Analysis of the U.S. Census Household Pulse Survey.
5. Pascual-Leone, A., et al. (1996). Repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression. Archives of General Psychiatry, 53(10), 869-874.
6. Rush, A. J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917.
7. O’Reardon, J. P., et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. Biological Psychiatry, 62(11), 1208-1216.
8. Berlim, M. T., Van den Eynde, F., & Daskalakis, Z. J. (2013). Efficacy and acceptability of high-frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: A systematic review and meta-analysis of randomized trials. Depression and Anxiety, 30(7), 614-623.
9. U.S. Food and Drug Administration. (2018). FDA permits marketing of transcranial magnetic stimulation for the treatment of OCD. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-ocd
10. Cole, E. J., et al. (2020). Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. American Journal of Psychiatry, 177(8), 720-729.
11. Pallanti, S., Hollander, E., & Goodman, W. K. (2004). A qualitative analysis of nonresponse: Management of treatment-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry, 65(Suppl 14), 6-10.
12. Carmi, S., et al. (2019). Repetitive transcranial magnetic stimulation for treatment-resistant obsessive-compulsive disorder: An effectiveness trial. The American Journal of Psychiatry, 176(1), 43-53. https://www.nature.com/articles/s41398-021-01453-0
13. George, M. S., & Aston-Jones, G. (2010). Noninvasive techniques for probing neurocircuitry in psychiatric disorders: Functional neuroimaging and beyond. Neuropsychopharmacology, 35(1), 1-2.
14. Bedder, M., & Parker, L. (2023). Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain.
